Reporters have learned that the internationally renowned academic journal *Vaccines* recently published a research paper entitled "Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Healthy Children Aged 12 to 15 Months." This study is the first to use Beijing Sinovac Biotech...Sinovac Biotech's (hereinafter referred to as "Sinovac") varicella live attenuated vaccine was compared head-to-head with another control vaccine that has passed WHO prequalification. The results showed that Sinovac's varicella live attenuated vaccine met the non-inferiority standard for immunogenicity and had better safety than the control vaccine.

This study was a randomized, double-blind, positive-control, non-inferiority phase III clinical trial conducted at San Juan de Dios Hospital in the Philippines. A total of 484 healthy children aged 12 to 15 months were enrolled and randomly assigned to receive either one dose of Sinovac varicella attenuated live vaccine (239 cases) or control vaccine (245 cases). The primary evaluation factor was the varicella-zoster virus antibody response rate (IgG ≥ 10 mIU/mL) 6 weeks after vaccination. The secondary evaluation factors were the geometric mean antibody concentration (GMC) and safety.

Chickenpox is a highly contagious disease caused by the varicella-zoster virus. It is one of the most common infectious diseases in the world and continues to cause a public health burden in many countries. Vaccination is considered the most economical and effective measure to prevent chickenpox.

This head-to-head study further refines the evidence-based framework for Sinovac's varicella-zoster vaccine within the global varicella control system, providing scientific data support for its widespread application. To date, Sinovac's varicella-zoster vaccine is the first and only varicella vaccine in China to receive WHO prequalification, and it has been introduced to nearly 20 countries and regions worldwide, with tens of millions of doses supplied cumulatively.

https://finance.eastmoney.com/a/202510283547200418.html